
    
      This is a Phase 2, randomized, double-blind, placebo-controlled, multiple ascending dose
      study to evaluate the efficacy and safety of multiple doses of the mavrilimumab (CAM-3001)
      (10 milligram [mg], 30 mg, 50 mg, and 100 mg) administered subcutaneously in adult subjects
      with moderately active RA.
    
  